Table 1.
Characterization and validation.
| Classification | Test | Result | Data |
|---|---|---|---|
| Morphology | Photography | Normal human pluripotent stem cell morphology | Not shown but available with author |
| Phenotype | Immunocytochemisty | Staining for expression of pluripotency markers: OCT4, NANOG and TRA-1-60 | Fig. 1 panel A– C |
| Flow cytometry | Assess cell surface marker expression: SSEA-3: 91% | Fig. 1 panel D | |
| Genotype | Karyotype (G-banding) and resolution | 46,XY | Fig. 1 panel F |
| Resolution 475– 525 | |||
| Identity | Microsatellite PCR (mPCR) | Not performed | – |
| STR analysis | PowerPlex 16HS (Promega) 16 sites. Match with donor | Submitted in archive with journal | |
| Mutation analysis (IF APPLICABLE) | Sequencing | – | – |
| Southern Blot OR WGS | – | – | |
| Microbiology and virology | Mycoplasma | Mycoplasma testing by luminescence. Negative. | Fig. 1 panel H |
| Differentiation potential | Embryoid body formation | Expression of genes in embryoid bodies: smooth muscle actin, Tuj-1 β-tubulin and α-feto protein. | Fig. 1 panel E |
| Donor screening (OPTIONAL) | HIV 1 + 2 hepatitis B, Hepatitis C | – | – |
| Genotype additional info (OPTIONAL) | Blood group genotyping | – | – |
| HLA tissue typing | – | – |